CDG Therapeutics (United States)

Recent papers from CDG Therapeutics (United States)

1. Directed evolution of chlorotoxin enhances MMP-2 recognition and improves CAR-T-cell activity in glioblastoma models in vitroFrontiers in Bioengineering and Biotechnology · 2026
2. Safety and Tolerability of a Modified Ublituximab Dosing Regimen: Updates From the ENHANCE Study (P9-19.002)Neurology · 2026
3. Real World Clinical Experience from ENABLE, the First Phase Four Observational Study for Patients With Relapsing Multiple Sclerosis Initiating Ublituximab (P9-19.005)Neurology · 2026
4. Disease outcomes with ublituximab in treatment-naïve participants: subpopulation analyses of the phase 3 ULTIMATE I and II studies in participants with relapsing multiple sclerosisFrontiers in Immunology · 2026
5. Efficacy of Ublituximab in People with Highly Active Relapsing Multiple SclerosisNeurology and Therapy · 2026
6. A chemotherapy‐free regimen of acalabrutinib, umbralisib and ublituximab achieved high response rates and undetectable minimal residual disease in patients with untreated mantle cell lymphomaBritish Journal of Haematology · 2025
7. Improvements in no evidence of disease activity with ublituximab vs. teriflunomide in the ULTIMATE phase 3 studies in relapsing multiple sclerosisFrontiers in Neurology · 2024
8. Ublituximab Significantly Reduces Radiological Disease Activity at 12 Weeks: Post-hoc analysis of Participants with Highly Active Disease in the ULTIMATE I & II Phase 3 Studies (P9-6.017)Neurology · 2024
9. Earlier Initiation of Ublituximab Treatment Is Associated with Improved Disability Outcomes Among Treatment Naïve Participants in ULTIMATE I and II (P9-6.001)Neurology · 2024
10. MS Relapse Redefined: Distinguishing True Relapses from Pseudoexacerbations in the ULTIMATE I and II Trials Comparing Ublituximab vs Teriflunomide (P3-6.001)Neurology · 2024
11. Chemogenetic inhibition of the lateral hypothalamus in rats: A simple but robust tool with high translational relevance to facilitate the development of central nervous system-targeted gene therapies2023
12. Response-adapted, time-limited venetoclax, umbralisib, and ublituximab for relapsed/refractory chronic lymphocytic leukemiaBlood Advances · 2023
13. Ublituximab, a Novel, Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), Demonstrates Enhanced Antibody-Dependent Cellular Cytotoxicity (ADCC) Relative to Other Anti-CD20 mAbs (P7-3.011)Neurology · 2023
14. G protein-coupled receptor 183 mediates the sensitization of Burkitt lymphoma tumors to CD47 immune checkpoint blockade by anti-CD20/PI3Kδi dual therapySHILAP Revista de lepidopterología · 2023
15. Characteristics and lipid lowering treatment patterns in patients tested for lipoprotein(a): A real-world US studyAmerican Journal of Preventive Cardiology · 2023
16. First-in-Human (FIH) Study of the Fully-Human Kappa-Lambda CD19/CD47 Bispecific Antibody TG-1801 in Patients (pts) with B-Cell LymphomaBlood · 2022
17. A Phase II Trial of Acalabrutinib in Combination with PI3Kδ Inhibitor Umbralisib and the Anti-CD20 Antibody Ublituximab (AU2) in Patients with Previously Untreated Mantle Cell Lymphoma (MCL)Blood · 2022
18. Ublituximab versus Teriflunomide in Relapsing Multiple SclerosisNew England Journal of Medicine · 2022
19. Functional Testing to Characterize and Stratify PI3K Inhibitor Responses in Chronic Lymphocytic LeukemiaClinical Cancer Research · 2022
20. Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2Blood Advances · 2022